Skip to main content
Erschienen in: Supportive Care in Cancer 4/2021

07.09.2020 | Original Article

The impact of pretreatment serum cobalamin and folate levels on complications and peripheral blood recovery during induction chemotherapy of leukemia: a cross-sectional study

verfasst von: Volkan Köse, Özlem Arman Bilir, Abdurrahman Kara, Namık Yaşar Özbek, Hüsniye Neşe Yaralı

Erschienen in: Supportive Care in Cancer | Ausgabe 4/2021

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We aimed to evaluate the impact of pretreatment folate and vitamin B12 deficiencies on the frequency of complications and peripheral blood recovery, in children with acute lymphoblastic leukemia (ALL).

Methods

Pre-induction serum folate and vitamin B12 levels of 88 newly diagnosed ALL patients were evaluated retrospectively. Folate < 3 ng/mL and vitamin B12 < 200 pg/mL were accepted as deficiency. Median hemoglobin, absolute neutrophil count (ANC), and platelet counts, transfusion needs, and complications such as mucositis, febrile neutropenia (FN), bleeding at diagnosis, at 15th and 33rd day of induction, were assessed. Recovery of peripheral blood count, which was defined as an ANC > 1.0 × 109/L and platelet count > 100 × 109/L at 33rd day of chemotherapy were also evaluated.

Results

Folate or vitamin B12 deficiencies were observed in 21 (23%) and 40 (45%) children, respectively. Peripheral blood counts, complications rates, and transfusion needs were not statistically different between deficient and normal level groups during induction. The number of febrile days, though not statistically significant, was higher in the both deficient groups. Seventeen of 40 (42.5%) patients with vitamin B12-deficient and 12 of 21 (57.1%) folate-deficient patients experienced at least one episode of FN during induction. FN was more common in folate-deficient group, but that was not statistically significant. Complete peripheral blood recovery at 33rd day of induction was seen in 40% in the vitamin B12-deficient group and 28.6% in folate-deficient group. Peripheral blood recovery rate at day 33 was also similar in both deficient and normal level groups.

Conclusion

Although pre-induction low serum levels of vitamin B12 and folate did not have statistically significant impact on disease-/treatment-related complications and peripheral blood recovery at induction, the frequency of FN and number of febrile day were higher in both deficiencies and folate-deficient patients, respectively.
Literatur
1.
Zurück zum Zitat SEER Cancer Statistics Review (1975-2014) National Cancer Institute. Accessed Nov 2016 SEER Cancer Statistics Review (1975-2014) National Cancer Institute. Accessed Nov 2016
4.
Zurück zum Zitat Oskarsson T, Söderhäll S, Arvidson J, Forestier E, Frandsen T, Hellebostad M, Lähteenmäki P, Jónsson Ó, Myrberg I, Heyman M, Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL relapse working group (2018) Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 65(4):e26909. https://doi.org/10.1002/pbc.26909CrossRef Oskarsson T, Söderhäll S, Arvidson J, Forestier E, Frandsen T, Hellebostad M, Lähteenmäki P, Jónsson Ó, Myrberg I, Heyman M, Nordic Society of Paediatric Haematology and Oncology (NOPHO) ALL relapse working group (2018) Treatment-related mortality in relapsed childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 65(4):e26909. https://​doi.​org/​10.​1002/​pbc.​26909CrossRef
5.
Zurück zum Zitat Prucker C, Attarbaschi A, Peters C, Dworzak M, Potschger U, Urban C, Fink F, Meister B, Schmitt K, Haas O, Gadner H, Mann G (2009) Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia 23(7):1264–1269. https://doi.org/10.1038/leu.2009.12CrossRefPubMed Prucker C, Attarbaschi A, Peters C, Dworzak M, Potschger U, Urban C, Fink F, Meister B, Schmitt K, Haas O, Gadner H, Mann G (2009) Induction death and treatment-related mortality in first remission of children with acute lymphoblastic leukemia: a population-based analysis of the Austrian Berlin-Frankfurt-Munster study group. Leukemia 23(7):1264–1269. https://​doi.​org/​10.​1038/​leu.​2009.​12CrossRefPubMed
9.
Zurück zum Zitat Seif A, Fisher B, Li Y, Torp K, Rheam D, Huang Y, Harris T, Shah A, Hall M, Fieldston E, Kavcic M, Vujkovic M, Bailey L, Kersun L, Reilly A, Rheingold S, Walker D, Aplenc R (2014) Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer 61(5):846–852. https://doi.org/10.1002/pbc.24855CrossRefPubMed Seif A, Fisher B, Li Y, Torp K, Rheam D, Huang Y, Harris T, Shah A, Hall M, Fieldston E, Kavcic M, Vujkovic M, Bailey L, Kersun L, Reilly A, Rheingold S, Walker D, Aplenc R (2014) Patient and hospital factors associated with induction mortality in acute lymphoblastic leukemia. Pediatr Blood Cancer 61(5):846–852. https://​doi.​org/​10.​1002/​pbc.​24855CrossRefPubMed
10.
13.
Zurück zum Zitat Koç A, Koçyiǧit A, Ulukanligil M, Demir N (2005) The incidence of vitamin B12 and folic acid deficiency in children aged 9-12 years in Şanlıurfa region and the relationship of these two vitamins with intestinal parasitic infections. J Chıldren’s Heal Dıseases 48(4):308–315 Koç A, Koçyiǧit A, Ulukanligil M, Demir N (2005) The incidence of vitamin B12 and folic acid deficiency in children aged 9-12 years in Şanlıurfa region and the relationship of these two vitamins with intestinal parasitic infections. J Chıldren’s Heal Dıseases 48(4):308–315
17.
Zurück zum Zitat Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (2017). Common Terminology Criteria for Adverse Events (CTCAE) v5.0 (2017).
18.
Zurück zum Zitat Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C, Raad I, Rolston K, Young J, Wingard J (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–e93. https://doi.org/10.1093/cid/cir073CrossRefPubMed Freifeld A, Bow E, Sepkowitz K, Boeckh M, Ito J, Mullen C, Raad I, Rolston K, Young J, Wingard J (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis 52(4):e56–e93. https://​doi.​org/​10.​1093/​cid/​cir073CrossRefPubMed
19.
Zurück zum Zitat Carmel R, Watkins D, Rosenblatt D (2015) Megaloblastic anemia. In: Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 8th Ed edn., pp 308-343 Carmel R, Watkins D, Rosenblatt D (2015) Megaloblastic anemia. In: Nathan and Oski’s Hematology and Oncology of Infancy and Childhood. 8th Ed edn., pp 308-343
26.
Zurück zum Zitat Moulik N, Kumar A (2014) Are concerns about folic acid supplementation in children with acute lymphoblastic leukemia justified? Indian Pediatr 51(9):754–755CrossRef Moulik N, Kumar A (2014) Are concerns about folic acid supplementation in children with acute lymphoblastic leukemia justified? Indian Pediatr 51(9):754–755CrossRef
29.
Zurück zum Zitat Tandon S, Singh K, Ruban A, Singh B, Mahdi A, Kumar A (2014) Estimation of serum folate and vitamin B12 levels in children with hematologic malignancies. Gomal J Med Sci 12:89–92 Tandon S, Singh K, Ruban A, Singh B, Mahdi A, Kumar A (2014) Estimation of serum folate and vitamin B12 levels in children with hematologic malignancies. Gomal J Med Sci 12:89–92
32.
34.
Zurück zum Zitat Green R (1995) Metabolite assays in cobalamin and folate deficiency. Baillieres Clin Haematol 8(3):533–566CrossRef Green R (1995) Metabolite assays in cobalamin and folate deficiency. Baillieres Clin Haematol 8(3):533–566CrossRef
Metadaten
Titel
The impact of pretreatment serum cobalamin and folate levels on complications and peripheral blood recovery during induction chemotherapy of leukemia: a cross-sectional study
verfasst von
Volkan Köse
Özlem Arman Bilir
Abdurrahman Kara
Namık Yaşar Özbek
Hüsniye Neşe Yaralı
Publikationsdatum
07.09.2020
Verlag
Springer Berlin Heidelberg
Erschienen in
Supportive Care in Cancer / Ausgabe 4/2021
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-020-05688-3

Weitere Artikel der Ausgabe 4/2021

Supportive Care in Cancer 4/2021 Zur Ausgabe

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.